Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease

International Journal of Impotence Research

Volumn 14, Issue 3, 2002, Pages 178-188

  Simonsen, U ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Erectile dysfunction; Heart failure; Hypertension; Interactions; Ischaemic heart disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; APOMORPHINE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC GMP; CYTOCHROME P450 3A4; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HEPARIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; LOOP DIURETIC AGENT; NITRATE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; PROSTAGLANDIN E1; SILDENAFIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HEART FAILURE; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RISK FACTOR; SYNCOPE; DRUG INTERACTION; IMPOTENCE; MALE; REVIEW;

CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; HUMAN; IMPOTENCE; MALE; HUMANS;

EID: 0036019860     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900846     Document Type: Article

References (121)

1. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
2. Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study
3. Incidence of erectile dysfunction in men 40 to 69 y old: Longitudinal results from the Massachusetts male aging study
4. Psychosocial outcome after coronary artery surgery
5. Male sexual dysfunction associated with coronary heart disease
6. Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971-1992
7. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men
8. Cigarette smoking and other vascular risk factors in vasculogenic impotence
9. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men
10. The prevalence and etiology of impotence in 101 male hypertensive outpatients
11. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine
12. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
13. Diuretic therapy for mild hypertension: The 'real' cost of treatment
14. MRC trial of treatment of mild hypertension: Principal results
15. The impact of diuretic therapy on reported sexual function
16. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
17. The effects of anti-hypertensive drugs on sexual function in men and women: A report from the DHSS Hypertension Care Computing Project (DHCCP)
18. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/hydrochlorothiazide
19. Hypertension is associated with severe erectile dysfunction
20. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference
21. Physiology of penile erection
22. Adrenoceptor-mediated regulation of the contractility in horse penile resistance arteries
23. Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection
24. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension
25. The effects of antihypertensive therapy on the quality of life
26. Bisoprolol and hypertension: Effects on sexual functioning in men
27. The effects of verapamil and propranolol on quality of life in hypertension
28. Calcium antagonists stimulate sperm motility in ejaculated human semen
29. Sexual function in hypertensive males treated with lisinopril or atenolol: A cross-over study
30. Sexual activity in hypertensive men treated with valsartan or carvedilol: A crossover study
31. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction
32. Moxisylyte: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence
33. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants
34. Erectile dysfunction due to atherosclerotic vascular disease: The development of an animal model
35. Nitric oxide and penile erection in streptozotocin-diabetic rats
36. Decreased erectile function in renal hypertensive rats
37. Impaired neurogenic and endothelium mediated relaxation of penile smooth muscle from diabetic men with impotence
38. Effect of aging on nitric oxide-mediated penile erection in rats
39. Relationship between cavernosal ischemia and corporal veno-occlusive dysfunction in an animal model
40. The penis is not protected - In hypertension there are vascular changes in the penis which are similar to those in other vascular beds
41. Morphological changes in cavernous tissue in spontaneously hypertensive rats
42. Antihypertensive drugs induce structural remodeling of the penile vasculature
43. ABC of heart failure. Management: Diuretics, ACE inhibitors, and nitrates
44. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
45. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
46. The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy
47. A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure
48. The effect of digoxin on mortality and morbidity in patients with heart failure
49. A possible mechanism for alteration of human erectile function by digoxin: Inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity
50. Contribution of K+ channels and ouabain-sensitive mechanisms to the endothelium-dependent relaxations of horse penile small arteries
51. Possible role of Na(+)-K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide
52. The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction
53. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
54. Mechanism of action of fibrates on lipid and lipoprotein metabolism
55. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
56. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
57. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction
58. Impotence in patients treated with clofibrate
59. Gemfibrozil-induced impotence
60. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction
61. Peroxisome proliferator activated receptor agonists
62. PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator
63. Simvastatin and impotence
64. Central nervous system effects of HMG CoA reductase inhibitors: Lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia
65. Simvastatin seems unlikely to cause impotence
66. Priapism as a complication of heparin therapy
67. Preservation of potency after treatment for priapism
68. Factors associated with waning sexual function among elderly men and prostate cancer patients
69. Assessment of erectogenic properties of apomorphine and yohimbine in man
70. Effect of apomorphine on penile tumescence in men with psychogenic impotence
71. Recovery of erectile function by the oral administration of apomorphine
72. Key issues from the clinical trials of apomorphine SL
73. Dopamine receptor pharmacology
74. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates
75. Efficacy and safety of fixed-dose and dose optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
76. Apomorphine potentiates vagal bradycardia
77. Effects of SK&F 85174, a DA-1/DA-2 receptor agonist, on pre- and post-ganglionic sympathetic neurotransmission to the heart
78. The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia
79. The pharmacology and clinical pharmacokinetics of apomorphine SL
80. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms
81. Oral phentolamine: An alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction
82. Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction
83. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients
84. Yohimbine: A clinical review
85. Yohimbine as a serotonergic agent: Evidence from receptor binding and drug discrimination
86. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials
87. Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197)
88. Effects of intrathecal and systemic administration of buspirone on genital reflexes and mating behavior in male rats
89. Herbs and alternative therapies in the hypertension clinic
90. Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine
91. Pharmacology of penile erection
92. Sildenafil: A review of its use in erectile dysfunction
93. Oral sildenafil in the treatment of erectile dysfunction
94. Acute myocardial infarction associated with sildenafil
95. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
96. Hemodynamic effects of sildenafil in men with severe coronary artery disease
97. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis
98. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
99. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina
100. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart
101. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication
102. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
103. Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway
104. Sildenafil inhibits hypoxia-induced pulmonary hypertension
105. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current
106. Inhibition of neuroeffector transmission in human vas deferens by sildenafil
107. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue
108. Anion and cation modulation of the guinea-pig ventricular action potential during beta-adrenoceptor stimulation
109. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs
110. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions
111. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
112. Interaction of sildenafil and indinavir when coadministered to HIV-positive patients
113. Overall cardiovascular profile of sildenafil citrate
114. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist
115. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction
116. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
117. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience
118. Intracavernous Alprostadil Alfadex-an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study
119. Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: A study of satisfaction and safety